Jang Hee Hong
Daejeon, Korea, South Korea
NCT Number: NCT04972539
To evaluate the safety and pharmacokinetic characteristics of AJU-A51 in healthy adults
Looking for future studies?
Notify Me19 year and older
All sexes
Interventional
Phase 1
Daejeon, Korea, South Korea
This study is to assess the safety and pharmacokinetic characteristics between co-administration of A51R1 with A51R2 and administration of AJU-A51.
This is an open-label, randomized, single-dose, 2x2 crossover study in healthy male and female subjects to assess the bioequivalence after taking the study drugs.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single oral dose AJU-A51(Dapagliflozin/Linagliptin) 10 mg / 5 mg FDC tablet
Other names: Test drug
Single oral dose A51R1(Dapagliflozin) 10 mg tablet and A51R2(Linagliptin) 5 mg tablet taken together
Other names: Reference drug
Time frame: predose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72hours post-dose
Area under the plasma concentration time curve of AJU-A51
Time frame: predose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72hours post-dose
The maximum concentration observed of AJU-A51 over blood sampling time.
AJU Pharm Co., Ltd.
Industry
A Randomized, Open, Single-dose, 2x2 Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Co-administration of A51R1 and A51R2 or Administration of AJU-A51 in Healthy Volunteers Under Fasting Conditions
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00340132
Body Weight, Body Weight Changes
Phoenix, Arizona, United States
View Trial DetailsNCT01878045
Diabetes Complications, Diabetes Mellitus
Phoenix, Arizona, United States
View Trial DetailsNCT04504968
Diabetes Mellitus, Diabetes Mellitus, Type 2
Bogotá, Colombia
View Trial DetailsNCT00339482
Cardiovascular Diseases, Diabetes Mellitus
Phoenix, Arizona, United States
View Trial Details